ClinicalTrials.gg
CompletedNCT04905667Updated May 27, 2021

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

A Phase 1 interventional study of GB221 and Herceptin in Breast Cancer, sponsored by Genor Biopharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-27.

Sponsored by Genor Biopharma Co., Ltd. (part of Edding Genor Group Holdings Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Nov 2019, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
927th of 1,519
87 · median 120
Started
2019
with 113 others
Phase 1
171 of 1,928
61 open now
Registered
732nd of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 927th largest by enrollment of the 1,519 interventional ones that give a count, is one of 114 that started in 2019, is one of 171 in phase 1, and was the 732nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and Herceptin ®.

Read the detailed description

Subjects will enroll in random order, and be divided into two groups, then receive a single dose (6 mg/kg) of GB221 or Herceptin ®, and accept observation for 42 days. Throughout the course, safety data will be collected.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • Pharmacokinetics
  • anti-HER-2 human monoclonal antibody
  • Herceptin
  • GB221
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Signed form;
    1. Healthy adult volunteers aged between 18 and 45, male or female;
    1. Medical examination as required within 28 days, (BMI) 19.0 \~ 24.0, weight≥50 kg for men, ≥45 kg for women, and≤ 75 kg for both;
    1. Agreed with taking reliable measures, and no fertility planning from the beginning to the end of the study within 6 months;
  • 5.Subject can communicate well with the investigators and complete the study according to the study regulations.

Exclusion criteria

Exclusion Criteria:

    1. Pregnant or lactating women, or positive in either blood or urine pregnancy test; or unwilling to take effective measures during the trial and within 6 months after the end of the trial at fertile age;
    1. Allergic constitution; or history of allergic to experimental drug ingredient or any drug or food or pollen; or abnormal serum immunoglobulin E (IgE) test;
    1. History of drug abuse, or positive urine test for drug;
    1. History of the central nervous system, cardiovascular system, kidney, liver, digestive system, respiratory system, metabolic system or other significant diseases. History of high blood pressure, or systolic blood pressure≥140 mmHg/diastolic blood pressure≥90 mmHg;
    1. Family history of cancer, or tumor markers (male: CEA, AFP, PSA, CA-125; Female: CEA, AFP, CA-153, CA-125) positive.
    1. Participated in other clinical trials of drug or used drugs harmful to major organs within 3 months;
    1. Blood donation within 3 months;
    1. Used prescription or OTC drugs within 14 days;
    1. (LVEF) \< 60%;
    1. or AST > 1.5 , Cr > ULN;
    1. WBC \< 0.8 LLN or > 1.2 ULN; ANC \< 0.8 LLN; \< 0.8 LLN; HGB \< 0.9LLN.
    1. HBs-Ag, -Ab, anti- or TP-Ab positive;
    1. Anti-drug antibody (ADA) test positive;
  • 14.History of psychosis;
    1. History of postural hypotension;
    1. More than 5 cigarettes per day;
    1. More than 28 units of alcohol per week; Or alcohol breath test positive within 24 hours before pre-dose;
    1. History of dizziness of blood or needle;
    1. Unsuitable for other reasons.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    GB221 group

    6 mg/kg, single dose, intravenous infusion, 90-100 min

    Drug: GB221

  • Active comparator
    Herceptin group

    6 mg/kg, single dose, intravenous infusion, 90-100 min

    Drug: Herceptin

Interventions

  • DrugGB221

    6 mg/kg, single dose, intravenous infusion, 90-100 min

  • 6 mg/kg, single dose, intravenous infusion, 90-100 min

06

What researchers measure

Primary outcomes

  1. AUC0-t

    compare the pharmacokinetic AUC0-t parameters of GB221 and Herceptin ®

    Time frame: Day 43

  2. AUC0-∞

    compare the pharmacokinetic AUC0-∞parameters of GB221 and Herceptin ®

    Time frame: Day 43

  3. Cmax

    compare the pharmacokinetic Cmax parameters of GB221 and Herceptin ®

    Time frame: Day 43

Secondary outcomes

  1. Tmax

    compare the pharmacokinetic Tmax parameters of GB221 and Herceptin ®

    Time frame: Day 43

  2. t1/2

    compare the pharmacokinetic t1/2 parameters of GB221 and Herceptin ®

    Time frame: Day 43

  3. CL

    compare the pharmacokinetic CL parameters of GB221 and Herceptin ®

    Time frame: Day 43

  4. Vd

    compare the pharmacokinetic Vd parameters of GB221 and Herceptin ®

    Time frame: Day 43

  5. Ke

    compare the pharmacokinetic Ke parameters of GB221 and Herceptin ®

    Time frame: Day 43

  6. ADA

    compare the incidence of ADA in of GB221 and Herceptin ® group

    Time frame: Day 43

  7. Nab

    compare the incidence of Nab in of GB221 and Herceptin ® group

    Time frame: Day 43

07

Study locations

1 site
  • The Fifth Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangzhou 510799, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Sep 2020, 9 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 9 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2021
First posted
May 27, 2021
StartActual
Nov 13, 2019
Primary completionActual
Sep 8, 2020
CompletionActual
Sep 11, 2020
Last update
May 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04905667
Responsible party
Sponsor
First posted
May 27, 2021
Start date
Nov 13, 2019
Primary completion
Sep 8, 2020
Completion
Sep 11, 2020
Last update
May 27, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GB221

Start the discussion